Status:
COMPLETED
EU PV for Retapamulin-Prescribing
Lead Sponsor:
GlaxoSmithKline
Conditions:
Impetigo
Eligibility:
All Genders
Brief Summary
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of imp...
Eligibility Criteria
Inclusion
- The study population will consist of all registered "research standard" patients on GPRD, as evaluated annually for five years. For each year of observation, the denominator of persons will be patients registered for at least one month during the prior calendar year. Hence, the five-year reporting period for distinct, non-overlapping, non-cumulative prescription use and will categorize persons by date of birth (mm/dd/year).
Exclusion
- Enrollment in GPRD of less than one month duration.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01153828
Start Date
November 1 2008
End Date
August 1 2012
Last Update
June 10 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.